Gilead Sciences stock (US3755581036): Q1 earnings beat with $2.03 EPS

Gilead Sciences released stronger-than-expected first-quarter 2026 results on May 13, 2026, reporting adjusted earnings per share of $2.03, surpassing the consensus estimate of $1.91, while revenue reached $6.96 billion, a 4.4% increase year-over-year, MarketBeat as of 05/13/2026. The biopharmaceutical firm also saw institutional interest, with Trek Financial LLC adding 13,041 shares on May 13. The stock closed at $133.05 on recent trading, down 1.40% that day but up 8.5% year-to-date from $122.74 on January 1, 2026, MarketBeat as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

Gilead Sciences: core business model

Gilead Sciences focuses on developing and commercializing therapies in virology, oncology, and inflammation. The company markets leading HIV treatments like Biktarvy, which drives a significant portion of its revenue. Its pipeline emphasizes innovative antivirals and cancer drugs, positioning it as a key player in the US biopharma sector listed on Nasdaq.

Main revenue and product drivers for Gilead Sciences

HIV franchises remain the cornerstone, with products generating steady US sales amid high demand. Oncology revenue is growing through drugs like Trodelvy, targeting solid tumors. Recent Q1 2026 results showed revenue up 4.4% to $6.96B for the period ending March 31, 2026, published May 13, 2026, ad-hoc-news as of 05/13/2026. This beat supports ongoing investments in R&D for US investors tracking biotech stability.

Industry trends and competitive position

The biopharma industry faces patent cliffs but benefits from US market growth in specialty drugs. Gilead holds a strong position in HIV with market-leading adherence profiles. Its diversification into oncology aligns with rising US cancer incidence, enhancing relevance for American portfolios.

Why Gilead Sciences matters for US investors

As a Nasdaq-listed firm headquartered in California, Gilead derives substantial revenue from the US healthcare system. Its HIV dominance and oncology expansion offer exposure to defensive and growth segments, key for US retail investors balancing stability and innovation.

Conclusion

Gilead Sciences demonstrated resilience with Q1 2026 earnings beating expectations on EPS and revenue growth. Institutional accumulation and year-to-date gains reflect market confidence. US investors monitor its HIV strength and oncology progress amid biopharma dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.